The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis

被引:17
作者
Cantley, M. D. [2 ]
Bartold, P. M. [1 ]
Marino, V. [1 ]
Reid, R. C. [3 ]
Fairlie, D. P. [3 ]
Wyszynski, R. N. [2 ]
Zilm, P. S. [1 ]
Haynes, D. R. [2 ]
机构
[1] Univ Adelaide, Sch Dent, Colgate Australian Clin Dent Res Ctr, Adelaide, SA 5005, Australia
[2] Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia
[3] Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
live-animal micro-computed tomography; periodontitis; chronic inflammation; osteoclasts; PROSTAGLANDIN E-2; OSTEOCLAST FORMATION; CELL CULTURES; DIFFERENTIATION; INFLAMMATION; RESORPTION; RECEPTOR; DISEASE; RATS; EP2;
D O I
10.1111/j.1600-0765.2008.01132.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Live-animal micro-computed tomography is a new and promising technique that can be used to quantify changes in bone volume for periodontal disease models. The major aim of this study was to develop the methodology of live-animal micro-computed tomography and to determine the effect of a novel secretory phospholipase A(2) inhibitor on alveolar bone loss. Periodontitis was induced in mice by oral infection with Porphyromonas gingivalis over a period of 13 wk, and live-animal micro-computed tomography scans were taken at different time-points to determine bone volume changes with disease progression. This enabled conclusions to be made as to when treatment was most likely to be effective. In addition, the model was used to investigate a novel drug, the secretory phospholipase A(2) inhibitor, KHO64, and its potential ability to inhibit osteoclast bone resorption and treat periodontitis. The results from live-animal micro-computed tomography scans revealed greater, statistically significant, bone volume loss in diseased mice compared with normal mice (p < 0.05). This corresponded to a larger area from the cemento-enamel junction to the alveolar bone crest, as assessed by stereo imaging (p < 0.001). These techniques can therefore detect and quantify alveolar bone loss. Both methods revealed that KHO64 had no significant effect on the volume of bone resorption. Live-animal micro-computed tomography is a robust, reproducible technique that clearly demonstrates significant time-dependent changes in alveolar bone volume in a small-animal model of periodontitis.
引用
收藏
页码:317 / 322
页数:6
相关论文
共 25 条
  • [1] Global epidemiology of periodontal diseases: an overview
    Albandar, JM
    Rams, TE
    [J]. PERIODONTOLOGY 2000, 2002, 29 : 7 - 10
  • [2] Assuma R, 1998, J IMMUNOL, V160, P403
  • [3] Genetic control of susceptibility to Porphyromonas gingivalis-induced alveolar bone loss in mice
    Baker, PJ
    Dixon, M
    Roopenian, DC
    [J]. INFECTION AND IMMUNITY, 2000, 68 (10) : 5864 - 5868
  • [4] Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes
    Bidgood, MJ
    Jamal, OS
    Cunningham, AM
    Brooks, PM
    Scott, KF
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (05) : 2790 - 2797
  • [5] Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells
    Fujita, D
    Yamashita, N
    Iita, S
    Amano, H
    Yamada, S
    Sakamoto, K
    [J]. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2003, 68 (05): : 351 - 358
  • [6] FULLER K, 1989, J BONE MINER RES, V4, P209
  • [7] Comparison of morphological effects of PGE2 and TGFβ on osteoclastogenesis induced by RANKL in mouse bone marrow cell cultures
    Gardner, Colin R.
    [J]. CELL AND TISSUE RESEARCH, 2007, 330 (01) : 111 - 121
  • [8] Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats
    Gregory, LS
    Kelly, WL
    Reid, RC
    Fairlie, DP
    Forwood, MR
    [J]. BONE, 2006, 39 (01) : 134 - 142
  • [9] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity
    Hansford, KA
    Reid, RC
    Clark, CI
    Tyndall, JDA
    Whitehouse, MW
    Guthrie, T
    McGeary, RP
    Schafer, K
    Martin, JL
    Fairlie, DP
    [J]. CHEMBIOCHEM, 2003, 4 (2-3) : 181 - 185
  • [10] Emerging and future therapies for the treatment of bone loss associated with chronic inflammation
    D. R. Haynes
    [J]. InflammoPharmacology, 2006, 14 (5-6) : 193 - 197